Keshu Zhou

2.4k total citations
111 papers, 785 citations indexed

About

Keshu Zhou is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Keshu Zhou has authored 111 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 51 papers in Genetics and 47 papers in Pathology and Forensic Medicine. Recurrent topics in Keshu Zhou's work include Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (45 papers) and CAR-T cell therapy research (38 papers). Keshu Zhou is often cited by papers focused on Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (45 papers) and CAR-T cell therapy research (38 papers). Keshu Zhou collaborates with scholars based in China, United States and Australia. Keshu Zhou's co-authors include Yongping Song, Kiyoshi Masuda, Masumi Yamagishi, Mitsuru Osaki, Jianfeng Zhou, Haiyi Guo, Zengjun Li, Dehui Zou, Jianda Hu and William Novotny and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Keshu Zhou

93 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keshu Zhou China	14	338	307	306	220	154	111	785
Georg Aue United States	16	434 1.3×	615 2.0×	199 0.7×	240 1.1×	267 1.7×	52	1.0k
Madlene Oelsner Germany	10	135 0.4×	214 0.7×	190 0.6×	373 1.7×	70 0.5×	11	667
Francesco Maura United States	18	229 0.7×	205 0.7×	315 1.0×	496 2.3×	580 3.8×	98	989
Siddha Kasar United States	14	351 1.0×	522 1.7×	170 0.6×	448 2.0×	134 0.9×	34	1.0k
Marie‐Paule Mellerin France	14	150 0.4×	176 0.6×	346 1.1×	415 1.9×	472 3.1×	18	871
Selda Samakoglu United States	12	258 0.8×	165 0.5×	353 1.2×	188 0.9×	62 0.4×	20	635
Blanca González‐Farré Spain	17	451 1.3×	238 0.8×	509 1.7×	275 1.3×	22 0.1×	57	935
Shruti Bhatt United States	14	190 0.6×	118 0.4×	274 0.9×	261 1.2×	155 1.0×	37	658
Anna Jankowska United States	15	100 0.3×	324 1.1×	185 0.6×	390 1.8×	494 3.2×	27	939
Michael Jeffrey Cho United States	7	176 0.5×	114 0.4×	334 1.1×	261 1.2×	43 0.3×	8	779

Countries citing papers authored by Keshu Zhou

Since Specialization

Citations

This map shows the geographic impact of Keshu Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keshu Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keshu Zhou more than expected).

Fields of papers citing papers by Keshu Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keshu Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keshu Zhou. The network helps show where Keshu Zhou may publish in the future.

Co-authorship network of co-authors of Keshu Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Keshu Zhou. A scholar is included among the top collaborators of Keshu Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keshu Zhou. Keshu Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Li‐Ming, Bailin Zhang, Hong Luo, et al.. (2025). Areca Nut Production, Imports, and Their Impact on Oral Cancer Incidence. Journal of Dental Research. 105(2). 207–216. 3 indexed citations

Zhou, Keshu, Hongyun Xing, Wuping Li, et al.. (2024). Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 144(Supplement 1). 4627–4627.

Wang, Xiangmin, Qing Zhang, Hongyuan Zhou, et al.. (2024). Impact of tocilizumab on anti‐CD19 chimeric antigen receptor T‐cell therapy in B‐cell acute lymphoblastic leukemia. Cancer. 130(15). 2660–2669. 3 indexed citations

Song, Zheng, Ying Cheng, Haiyan Yang, et al.. (2024). Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Blood. 144(Supplement 1). 986–986. 1 indexed citations

Song, Yuqin, Jianyong Li, Keshu Zhou, et al.. (2024). Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma. 65(5). 647–652. 1 indexed citations

Yang, Jianliang, Yongping Song, Keshu Zhou, et al.. (2024). Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7060–7060. 2 indexed citations

Yang, Shenmiao, Haiwen Huang, Keshu Zhou, et al.. (2024). Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial. Annals of Hematology. 104(1). 701–712. 1 indexed citations

Yang, Jianliang, Keshu Zhou, Zhiming Li, et al.. (2024). Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study. Journal of Hematology & Oncology. 17(1). 123–123. 3 indexed citations

Yan, Zheng, Shuna Yao, Haiying Wang, et al.. (2023). Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review. Journal of Microbiology Immunology and Infection. 56(4). 747–756. 1 indexed citations

10.

Huang, Zhenghua, Zhen Li, Fengkuan Yu, et al.. (2023). A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy. Frontiers in Oncology. 13. 1162413–1162413.

11.

Liu, Yanyan, et al.. (2023). Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2. Biochemical and Biophysical Research Communications. 676. 21–29. 3 indexed citations

12.

Qi, Junyuan, Mingyuan Sun, Keshu Zhou, et al.. (2023). EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 6230–6230. 1 indexed citations

13.

Li, Zhen, Fengkuan Yu, Yanli Zhang, et al.. (2023). Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma. Frontiers in Oncology. 13. 1193237–1193237. 4 indexed citations

14.

Jin, Jie, Qingqing Cai, Liling Zhang, et al.. (2023). Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26). Blood. 142(Supplement 1). 4430–4430. 3 indexed citations

15.

An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations

16.

Han, Lu, Jishuai Zhang, Jian Zhou, et al.. (2021). Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. Leukemia. 35(10). 3002–3006. 33 indexed citations

17.

Song, Yuqin, Keshu Zhou, Dehui Zou, et al.. (2020). Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clinical Cancer Research. 26(16). 4216–4224. 111 indexed citations

18.

Zhou, Keshu, Qing Zhang, Huifang Zhao, et al.. (2017). Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia. Oncotarget. 8(15). 25469–25481. 18 indexed citations

19.

Zhou, Keshu, Qizhou Zhang, Yong Liu, et al.. (2017). Aberrant histone modification in CD19+ B cells of the patients with chronic lymphocytic leukemia. SHILAP Revista de lepidopterología. 1 indexed citations

20.

Yi, Shuhua, Zengjun Li, Dehui Zou, et al.. (2016). Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genetics in Medicine. 19(2). 182–191. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact